Literature DB >> 14961903

Morbidity and cost of atopic eczema in Australia.

Nicole Jenner1, Jan Campbell, Robin Marks.   

Abstract

The severity, morbidity and financial costs of atopic eczema (AE) were assessed during a 1-year prospective study of a cohort of 85 people aged 14-63 years (mean 36 years) with the disease. A dermatologist examined each participant using the Six Area Six Sign Atopic Dermatitis severity scoring system to classify severity. Participants completed a Dermatology Life Quality Index (DLQI), a Nottingham Eczema Severity Score (NESS) and an ongoing diary of health-care consultations and treatment costs. Follow up by mail to each participant was conducted every 2 months and participants completed a NESS, a DLQI and a diary of costs incurred. The DLQI data revealed that 36% spent over 10 min per day applying treatments, 28% indicated that AE influenced the clothes they wore, 21% felt embarrassed by their skin and 15% reported problems with treatments. There appeared to be a relationship between increased morbidity and increased severity. The average annual out-of-pocket cost for products used for treatment was A$425, ranging from A$13.50 to over A$2000 per individual. The average out-of-pocket cost for medical consultations was A$120, ranging from zero to over A$800 per individual. Although there were concerns about the reproducibility of the severity and morbidity measures, the data showed that AE can have substantial effects both financially and from a personal perspective for those affected.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14961903     DOI: 10.1111/j.1440-0960.2004.00046.x

Source DB:  PubMed          Journal:  Australas J Dermatol        ISSN: 0004-8380            Impact factor:   2.875


  6 in total

Review 1.  The potential action of SSRIs in the treatment of skin diseases including atopic dermatitis and slow-healing wounds.

Authors:  Aneta Kiecka; Marian Szczepanik
Journal:  Pharmacol Rep       Date:  2022-10-07       Impact factor: 3.919

Review 2.  Emollients and moisturisers for eczema.

Authors:  Esther J van Zuuren; Zbys Fedorowicz; Robin Christensen; Adriana Lavrijsen; Bernd WM Arents
Journal:  Cochrane Database Syst Rev       Date:  2017-02-06

Review 3.  Health outcome measures in atopic dermatitis: a systematic review of trends in disease severity and quality-of-life instruments 1985-2010.

Authors:  Balvinder Rehal; April W Armstrong; April Armstrong
Journal:  PLoS One       Date:  2011-04-13       Impact factor: 3.240

4.  Cost of care of atopic dermatitis in India.

Authors:  Sanjeev Handa; Naresh Jain; Tarun Narang
Journal:  Indian J Dermatol       Date:  2015 Mar-Apr       Impact factor: 1.494

Review 5.  Understanding economic evidence for the prevention and treatment of atopic eczema.

Authors:  T H Sach; E McManus; N J Levell
Journal:  Br J Dermatol       Date:  2019-04-11       Impact factor: 9.302

Review 6.  Immune Pathways in Atopic Dermatitis, and Definition of Biomarkers through Broad and Targeted Therapeutics.

Authors:  Yasaman Mansouri; Emma Guttman-Yassky
Journal:  J Clin Med       Date:  2015-04-29       Impact factor: 4.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.